Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPLE: Abicipar pegol in neovascular AMD
NCT03539549Phase 2Completed
- Sponsor
- Allergan
- Start
- May 2018
- Primary completion
- Feb 2019
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abicipar pegol in neovascular age-related macular degeneration (NVAMD), sponsored by Allergan. Started May 2018; status: completed.
02
Drugs
abicipar pegol
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT03539549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539549.